(Q33802744)

29 July 2017

1 reference

title

Obesity drugs and the heart (English)

1 reference

29 July 2017

0 references

Connolly HM

1

1 reference

PubMed ID

10609092

29 July 2017

McGoon MD

series ordinal

2

1 reference

29 July 2017

1 December 1999

1 reference

Current Problems in Cardiology

29 July 2017

1 reference

29 July 2017

24

1 reference

29 July 2017

12

1 reference

29 July 2017

745-792

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

29 July 2017

1 reference

7 January 2021

Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Obesity, health services use, and health care costs among members of a health maintenance organization.

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Health implications of overweight and obesity in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Drugs that enhance central serotoninergic transmission diminish elective carbohydrate consumption by rats

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Fenfluramine and fluoxetine spare protein consumption while suppressing caloric intake by rats

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Aminorex to fen/phen: an epidemic foretold

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Primary pulmonary hypertension: natural history and the importance of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Factors that influence the outcome of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Hypertensive pulmonary vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Antinuclear antibodies in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Evidence for the association of unexplained pulmonary hypertension in children with the major histocompatibility complex

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Pulmonary vascular disease in secundum atrial septal defect with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Endothelin receptor antagonists in a beagle model of pulmonary hypertension: contribution to possible potential therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Familial primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Coancestry in apparently sporadic primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

The presence of genetic anticipation suggests that the molecular basis of familial primary pulmonary hypertension may be trinucleotide repeat expansion

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Coexistent pulmonary and portal hypertension: morphologic and clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Distinctive clinical features of portopulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

An epidemic of pulmonary hypertension after toxic rapeseed oil ingestion in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

The Cause and Pathogenesis of the Eosinophilia-Myalgia Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Pulmonary hypertension and fenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Irreversible pulmonary hypertension after treatment with fenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Fenfluramine--induced irreversible pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Pulmonary hypertension and dexfenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Pulmonary hypertension and dexfenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Primary pulmonary hypertension and fenfluramine use

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Appetite suppressants and primary pulmonary hypertension in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

International Primary Pulmonary Hypertension Study

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Primary pulmonary hypertension and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Editorial: Pulmonary hypertension and oral contraceptive usage

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Increased plasma serotonin in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Cardiac murmurs and endocardial fibrosis associated with methysergide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Development of heart valve lesions during methysergide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Doppler echocardiography: theory, instrumentation, technique, and application

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Prevention of bacterial endocarditis. Recommendations by the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Treatment of the carcinoid tumor and the malignant carcinoid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Cardiac murmurs indicative of aortic valve disease with chronic and excessive intake of ergotamine

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

The appetite suppressant d-fenfluramine induces apoptosis in human serotonergic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Endocardial fibrosis associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

Digital necrosis associated with dexfenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0146-2806%2899%2990013-0

7 January 2021

10.1016/S0146-2806(99)90013-0

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10609092